Xianghong Guan

Xianghong Guan

Auto-generated profile, based on publicly available information

Xianghong Guan

Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota College of Pharmacy, 717 Delaware Street, SE, Minneapolis, Minnesota 55414, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XGXianghong Guan
Xianghong Guan
NCNarsihmulu Cheryala
Narsihmulu Cheryala
RKRezaul Md. Karim
Rezaul Md. Karim
ACAlice Chan
Alice Chan
NBNorbert Berndt
Norbert Berndt
ESErnst Schonbrunn
Ernst Schonbrunn

15 April 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
TLTaimeng Liang
Taimeng Liang
XGXianghong Guan
Xianghong Guan
ACAlice Chan
Alice Chan
PKPrakriti Kalra
Prakriti Kalra
RSRui Shi
Rui Shi
GGGunda I Georg
Gunda I Georg
The first bromodomain of the BET protein BRDT (BRDT-BD1) possesses a unique Arg54 residue at the terminus of the ZA channel, absent in other BET family members. We explored this structural uniqueness with 23 analogs of the BET/kinase inhibitor SG3–179, each bearing an amino acid side chain to enable potential interactions between the positively charged arginine group and the negatively charged carboxylate groups. In an AlphaScreen assay, serine analog 13 showed 35-fold selectivity for BRDT-T over BRD4-T. The BRDT-BD1 cocrystal structure with glutamic acid analog 14 showed no interaction with Arg54, suggesting that the observed preference may be related to differences in the structured water molecules. Compound 13 displayed exceptional in vitro metabolic stability but had limited cellular permeability in MDCK-MDR1 cells. Compounds 13 and 14 are among the best BRDT-BD1-preferring inhibitors reported to date and demonstrate a significant step toward identifying highly selective BRDT inhibitors for male contraception.